Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

About this update from Azenta, Inc.

[{"type":"text","content":"BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2025.\nThe results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale.\nQuarter Ended\nDollars in millions, except per share data\nMarch 31,\nDecember 31,\nMarch 31,\nChange\n2025\n2024\n2024\nPrior Qtr\nPrior Yr.\nRevenue from Continuing Operations\n$\n143\n$\n148\n$\n136\n(3)\n%\n5\n%\nOrganic growth\n6\n%\nSample Management Solutions\n$\n80\n$\n81\n$\n74\n(2)\n%\n8\n%\nMultiomics\n$\n64\n$\n66\n$\n62\n(4)\n%\n2\n%\nDiluted EPS Continuing Operations\n$\n(0.40)\n$\n(0.21)\n$\n(0.29)\n(93)\n%\n(36)\n%\nDiluted EPS Total\n$\n(0.88)\n$\n(0.29)\n$\n(2.47)\nNM\n64\n%\nNon-GAAP Diluted EPS Continuing Operations\n$\n0.05\n$\n0.08\n$\n0.06\n(43)\n%\n(23)\n%\nAdjusted EBITDA - Continuing Operations\n$\n14\n$\n13\n$\n8\n7\n%\n75\n%\nAdjusted EBITDA Margin - Continuing Operations\n10.0\n%\n9.0\n%\n6.0\n%\nManagement Comments \n\"We delivered another quarter of strong performance in an evolving and uncertain macroeconomic environment. Our performance in the second quarter and first half of our fiscal year demonstrates the resilience of our portfolio and the dedication of our teams that focus on our customers with our clearly differentiated products and services,\" said John Marotta, President and CEO. \"We have a healthy balance sheet, and strong cash position, which provides optionality to continue investing in our long-term growth plans while maintaining our continued disciplined in capital deployment. We remain confident in our positioning and disciplined in how we operate the business while navigating these uncertain times.\" \nSecond Quarter Fiscal 2025 Results - Continuing Operations\nRevenue was $143 million, up 5% year over year. Organic revenue, which excludes the impact from foreign exchange, was up 6% year over year. The year-over-year revenue increase was attributable to higher Sample Management Solutions and Multiomics revenues.Sample Management Solutions revenue was $80 million, up 8% year over year.Organic revenue grew 8%, mainly driven by higher revenues in Sample Repository Solutions and Core Products, particularly in Consumables...

More updates from Azenta, Inc.